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irolimus-Eluting Stent Implantation
or Unprotected Left Main Coronary Artery Stenosis
omparison With Bare Metal Stent Implantation
eung-Jung Park, MD, PHD,* Young-Hak Kim, MD,* Bong-Ki Lee, MD,* Seung-Whan Lee, MD,*
heol Whan Lee, MD, PHD,* Myeong-Ki Hong, MD, PHD,* Jae-Joong Kim, MD, PHD,*
ary S. Mintz, MD,† Seong-Wook Park, MD, PHD*
eoul, Korea; and New York, New York
OBJECTIVES This study was designed to compare the clinical and angiographic outcomes of sirolimus-
eluting stent (SES) and bare metal stent (BMS) implantation for unprotected left main
coronary artery (LMCA) stenosis.
BACKGROUND The safety and effectiveness of SES implantation for unprotected LMCA stenosis have not
been ascertained.
METHODS Elective SES implantation for de novo unprotected LMCA stenosis was performed in 102
consecutive patients with preserved left ventricular function from March 2003 to March 2004.
Data from this group were compared to those from 121 patients treated with BMS during the
preceding two years.
RESULTS Compared to the BMS group, the SES group received more direct stenting, had fewer
debulking atherectomies, had a greater number of stents, had more segments stented, and
underwent more bifurcation stenting. The procedural success rate was 100% for both groups.
There were no incidents of death, stent thrombosis, Q-wave myocardial infarction (MI), or
emergent bypass surgery during hospitalization in either group. Despite less acute gain (2.06 
0.56 mm vs. 2.73  0.73 mm, p  0.001) in the SES group, SES patients showed a lower
late lumen loss (0.05  0.57 mm vs. 1.27  0.90 mm, p  0.001) and a lower six-month
angiographic restenosis rate (7.0% vs. 30.3%, p  0.001) versus the BMS group. At 12
months, the rate of freedom from death, MI, and target lesion revascularization was 98.0 
1.4% in the SES group and 81.4  3.7% in the BMS group (p  0.0003).
CONCLUSIONS Sirolimus-eluting stent implantation for unprotected LMCA stenosis appears safe with
regard to acute and midterm complications and is more effective in preventing restenosis
compared to BMS implantation. (J Am Coll Cardiol 2005;45:351–6) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.039American College of Cardiology Foundation
o
p
l
M
S
c
s
c
w
d
c
m
d
m
n
d
w
teveral studies have demonstrated the safety and feasibility
f unprotected left main coronary artery (LMCA) interven-
ion using bare metal stents (BMS) (1–8). In-stent reste-
osis is the main limit to the long-term efficacy of coronary
tenting and may be associated with increased long-term
ortality of unprotected LMCA intervention (5).
The sirolimus-eluting stent (SES) (Cypher, Cordis,
ohnson and Johnson Corp, Miami, Florida) markedly
ecreases in-stent restenosis in elective patients with rela-
ively simple coronary lesions (9,10). Recent reports from
he RESEARCH registry suggest that SES implantation
or LMCA stenosis may lead to favorable clinical outcomes
y decreasing restenosis (11,12). However, these studies
ere limited by their small numbers of patients, heteroge-
eity of inclusion criteria, and low rates of angiographic
ollow-up.
From the *Department of Medicine, University of Ulsan College of Medicine,
san Medical Center, Seoul, Korea; and the †Cardiovascular Research Foundation,
ew York, New York. This study was partly supported by the Cardiovascular
esearch Foundation, Seoul, Korea.
Manuscript received July 27, 2004; revised manuscript received September 27,
004, accepted October 4, 2004.The present study reports the clinical and angiographic
utcomes following elective SES implantation and com-
ares these outcomes with those of BMS implantation in a
arge number of patients with unprotected LMCA stenoses.
ETHODS
tudy population. From March 2003 to March 2004, 102
onsecutive patients with de novo unprotected LMCA
tenoses underwent elective SES stenting (SES group). The
ontrol group consisted of 121 consecutive patients treated
ith BMS implantation for unprotected LMCA stenoses
uring the preceding two years (BMS group). The inclusion
riteria were symptomatic LMCA disease or documented
yocardial ischemia and angiographic evidence of 50%
iameter stenosis of the LMCA suitable for stent place-
ent. The LMCA was considered unprotected if there were
o patent coronary artery bypass grafts to the left anterior
escending artery or left circumflex artery (LCX). Patients
ith a contraindication for antiplatelet or anticoagulation
herapy, or left ventricular dysfunction (ejection fraction
40%), were excluded. Informed written consent was ob-
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elsinki.
tenting procedure. In general, LMCA intervention was
erformed as previously described (13). Predilation was
outinely performed for BMS implantations, whereas the
ES group underwent predilation only in selected cases with
ery tight stenoses in order to minimize balloon injury to the
rterial wall. Most lesions at the ostium or shaft without
nvolvement of the bifurcation were treated with a single
tent. Bifurcation lesions were treated using one of the four
ollowing stenting strategies at the operator’s discretion:
tenting across the LCX ostium, kissing stenting, T stent-
ng, or the Crush technique. The techniques of stenting
cross the LCX ostium, kissing stenting, and T stenting
ere performed as previously described (6). In the BMS
roup, bifurcation stenting such as kissing stenting or T
tenting was rarely used because our previous study showed
hese complex stenting techniques did not result in superior
utcomes compared to simple stenting techniques (6). The
rush technique is a relatively new bifurcation stenting
echnique involving drug-eluting stents for bifurcation cor-
nary lesions (14). Final kissing balloon dilation was per-
ormed in cases with suboptimal results at the LCX ostium
fter bifurcation treatment and in most Crush technique
ases (n  10). Stenting across the LCX ostium was
requently adopted in patients with normal or diminutive
2.5 mm) LCX, whereas complex techniques such as
issing stenting, T stenting, and Crush technique were used
n cases of a diseased LCX.
The use of intravascular ultrasound (IVUS) was strongly
ncouraged to achieve optimal stent placement. In the BMS
roup, debulking atherectomy before stenting was per-
ormed to decrease plaque burden in suitable cases. In
ontrast, in the SES group debulking atherectomy was used
n only three cases to facilitate stent delivery to the target
esions. An intra-aortic balloon pump was used in selected
ases for hemodynamic support. Postdilation with balloons
arger than the nominal stent size was performed in cases of
uboptimal stent expansion according to IVUS examination.
se of glycoprotein IIb/IIIa inhibitors was restricted be-
ause of the limited reimbursement in this country, and
heir use was left to the operator’s discretion. Until May
Abbreviations and Acronyms
BMS  bare metal stent
CSA  cross-sectional area
EEM  external elastic membrane
IVUS  intravascular ultrasound
LCX  left circumflex artery
LMCA  left main coronary artery
MACE  major adverse cardiac event
MI  myocardial infarction
QCA  quantitative coronary angiography
SES  sirolimus-eluting stent003, the available SES size was 3.0 mm, and 16 patients
Veceived this size. All patients received aspirin (200 mg/day)
ndefinitely and a loading dose of 300 mg clopidogrel,
ollowed by 75 mg daily in a single dose for six months in
he SES group and for one month in the BMS group. In
ddition, 200 mg cilostazol was administered as a loading
ose, followed by 100 mg twice daily for one month in the
ES group (15). A loading dose of clopidogrel or cilostazol
as administered within 24 h before the procedure. Com-
ined use of cilostazol after SES implantation was based on
ur unpublished findings, which showed a superior clinical
utcome when using triple antiplatelet combination com-
ared to double conventional combination therapy after
tenting for complex coronary lesions.
uantitative coronary angiography (QCA) analysis. Coro-
ary angiography was performed after administering 0.2 mg
ntracoronary nitroglycerin. Coronary angiographic results
ere analyzed by two experienced angiographers not in-
olved in the stenting procedures. Using the guiding cath-
ter for magnification calibration and an online QCA
ystem (ANCOR V2.0, Siemens, Solna, Sweden), minimal
umen diameter, percent diameter stenosis, and reference
essel diameter were measured before and after intervention
nd at follow-up from diastolic frames in single, matched
iews showing the smallest lumen diameter. The diameters
f normal segments proximal and distal to the treated area
ere averaged to determine the reference diameter. In ostial
nd bifurcation lesions, adjacent normal segments were used
s a reference. The acute gain was calculated as the differ-
nce between the minimal lumen diameter before and after
he procedure. The late loss was defined as the difference in
inimal lumen diameter after the procedure and at
ollow-up.
able 1. Baseline Clinical Characteristics
SES BMS
p
Value
atients 102 121
ge, yrs 60.3  11.1 57.6  11.9 0.084
en 76 (74.5) 87 (71.9) 0.762
ardiac risk factors
Hypertension 48 (47.1) 44 (36.4) 0.103
Diabetes mellitus 29 (28.4) 26 (21.5) 0.231
Hypercholesterolemia
(total cholesterol
200 mg/dl)
18 (17.6) 27 (22.3) 0.387
Current smoking 28 (27.5) 36 (29.8) 0.705
revious percutaneous
coronary intervention
13 (12.7) 9 (7.4) 0.185
linical manifestation 0.234
Stable angina 41 (40.2) 39 (32.2)
Unstable angina 51 (50.0) 74 (61.2)
Myocardial infarction
within 2 weeks
10 (9.8) 8 (6.6)
ultivessel involvement
(2 vessels)
59 (58.4) 13 (10.7) 0.001
eft ventricular ejection
fraction, %
60.4  8.4 61.8  6.8 0.152alues represent number (%) or mean  1SD.
BMS  bare metal stent; SES  sirolimus-eluting stent.
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ervention IVUS images were obtained after administering
.2 mg intracoronary nitroglycerin using a commercial IVUS
ystem (SciMed/Boston Scientific, San Jose, California) and
otorized pullback at 0.5 mm/s. The external elastic mem-
rane (EEM) and lumen cross-sectional areas (CSA) were
easured using computerized planimetry, according to
alidated and published protocols (16–18). The plaque
urden (%) was measured as: 100  (EEM CSA  lumen
SA)/EEM CSA. After intervention, the lesion site was
he image slice with the smallest lumen CSA.
ollow-up. All patients were evaluated clinically by office
isits or telephone interviews at one, three, and six months,
nd then every four months after stenting. Repeat coronary
ngiography was routinely performed six months after
tenting or earlier if clinically indicated by symptoms or
ocumentation of myocardial ischemia.
efinition. Procedural success was defined as a Thrombol-
sis In Myocardial Infarction flow grade 3 and 30%
esidual diameter stenosis by QCA, without major proce-
ural or in-hospital complications such as death, Q-wave
yocardial infarction (MI), or emergent bypass surgery. A
ajor adverse cardiac event (MACE) was defined as the
ccurrence of cardiac death, nonfatal MI, and target lesion
evascularization during the follow-up period. Deaths that
ould not be classified were considered cardiac-related.
ngiographic restenosis was defined as a diameter stenosis
f 50% at the target site or the major side branches, such
s the left anterior descending artery or the LCX. An
able 2. Quantitative Angiographic Characteristics
SES BMS
p
Value
esions 102 121
esion location 0.001
Ostium 4 (23.5) 58 (48.3)
Shaft 6 (5.9) 11 (9.2)
Bifurcation 72 (70.6) 51 (42.5)
eference vessel diameter, mm 3.46  0.65 3.98  0.69 0.001
esion length, mm 20.9  15.5 10.9  5.3 0.001
inimal lumen diameter, mm
Baseline 1.31  0.57 1.35  0.58 0.552
Final 3.36  0.47 4.08  0.57 0.001
Follow-up 3.25  0.53 2.78  1.11 0.001
iameter stenosis, %
Baseline 62.0  14.5 65.7  14.8 0.066
Final 0.8  15 3.3  11.8 0.027
Follow-up 10.1  15.3 30.0  25.9 0.001
cute gain, mm 2.06  0.56 2.73  0.73 0.001
ate loss, mm 0.05  0.57 1.27  0.90 0.001
estenosis
Follow-up angiography 86 (84.3) 99 (81.8) 0.874
Overall 6 (7.0) 30 (30.3) 0.001
Main vessel 2 (2.3) 26 (26.3) 0.001
Ostial circumflex artery 4 (4.7) 13 (13.1) 0.072
alues represent number (%) or mean  1 SD.
Abbreviations as in Table 1.ntreated diminutive LCX with a diameter stenosis of
V50% after the procedure and at follow-up was not con-
idered restenosed.
tatistical analysis. Data are expressed as mean  1 SD
or continuous variables and as frequencies for categorical
ariables. Differences between groups were assessed using
hi-square statistics for categorical variables and Student t
est for continuous variables. Clinical outcomes after one
ear were compared because the two groups were treated at
ifferent times. Major adverse cardiac event-free survival
istributions were estimated according to the Kaplan-Meier
ethod. The log-rank test was used to compare MACE-
ree survival between the two groups. A value p  0.05 was
onsidered to represent a significant difference. Statistical
nalysis was performed using commercially available soft-
are (SPSS 11 for windows, SPSS Inc., Chicago, Illinois).
ESULTS
atient and lesion characteristics. The baseline clinical
nd angiographic characteristics of patients are shown in
ables 1 and 2. Compared to the BMS group, the SES
roup had more multivessel involvement (58.4% vs. 10.7%,
 0.001), more bifurcation lesions (70.6% vs. 42.5%, p 
.001), a smaller reference diameter (3.46  0.65 mm vs.
.98  0.69 mm, p  0.001), and a longer lesion length
20.9  15.5 mm vs. 10.9  5.3 mm, p  0.001).
rocedural results. Procedural characteristics are summa-
ized in Table 3. Compared to the BMS group, the SES
able 3. Procedural Characteristics
SES BMS
p
Value
atients 102 121
ntervention of other coronary
lesions
43 (42.2) 42 (34.7) 0.254
irect stenting 46 (45.1) 21 (17.4) 0.001
ebulking coronary
atherectomy
3 (2.9) 40 (33.1) 0.001
se of glycoprotein IIb/IIIa
inhibitors
8 (7.8) 6 (5.0) 0.376
se of additional high-pressure
balloons
60 (58.8) 24 (19.8) 0.001
uidance of intravascular
ultrasound
88 (86.3) 91 (75.2) 0.039
upport of intra-aortic balloon
pump
5 (4.9) 5 (4.1) 0.782
tents per patient 2.1  1.0 1.6  0.7 0.001
tents per lesion 1.6  0.9 1.1  0.4 0.001
ontiguous stent length, mm 26.6  18.1 13.3  5.5 0.001
aximal balloon size, mm 3.90  0.44 4.39  0.55 0.001
alloon-to-artery ratio 1.1  0.3 1.1  0.2 0.290
aximal inflation pressure, atm 18.5  2.8 14.0  2.6 0.001
reatment strategy for
bifurcation lesions
0.001
Stenting across left
circumflex artery
43 (59.7) 42 (82.4)
Kissing stenting 17 (23.6) 1 (2.0)
T stenting 1 (1.4) 8 (15.7)
Crush technique 11 (15.3) 0alues represent number (%) or mean  1 SD.
Abbreviations as in Table 1.
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therectomies, had more stents implanted, and had more
egments stented. In addition, IVUS guidance and addi-
ional high-pressure balloons were used more frequently in
he SES group compared to the BMS group. Extreme
verdilation with a balloon 1 mm larger than the nominal
tent size was performed in 18 SES patients and four BMS
atients (p  0.001). Bifurcation stenting, including kissing
tenting, T stenting, or Crush technique of bifurcation
MCA lesions, was performed in 40.3% of the SES group
nd in 17.6% of the BMS group (p  0.010).
The procedural success rate was 100% in both groups.
eriprocedural creatine kinase-MB elevation 3 times nor-
al developed in seven SES patients (6.9%) and in 10 BMS
atients (8.3%) (p  0.69). There were no incidents of
eath, stent thrombosis, Q-wave MI, or emergent bypass
urgery during hospitalization in either group. Quantitative
ngiographic and IVUS results after the procedures are
hown in Tables 2 and 4. We found that the QCA minimal
umen diameter (4.08  0.57 mm vs. 3.36  0.47mm, p 
.001) and IVUS lesion lumen CSA (12.41 3.20 mm2 vs.
.62  2.57 mm2, p  0.001) after procedure were larger
wing to greater acute lumen gain (2.73  0.73 mm vs. 2.06
0.56 mm, p 0.001) in the BMS group compared to the
ES group.
ollow-up results. Six-month angiographic follow-up was
erformed on 86 SES patients (84.3%) and 99 BMS
atients (81.8%). The QCA results at follow-up are shown
n Table 2. Late lumen loss (0.05  0.57 mm vs. 1.27 
.90 mm, p 0.001) and the overall angiographic restenosis
ate (7.0% vs. 30.3%, p  0.001) were significantly lower in
able 4. Intravascular Ultrasound Measurements at the
esion Segment
SES BMS
p
Value
efore procedure
Lumen CSA, mm2 3.24  1.33 2.86  1.08 0.095
EEM CSA, mm2 18.95  5.06 17.73  6.65 0.285
Plaque burden, % 82.4  7.0 81.5  9.7 0.605
fter procedure
Lumen CSA, mm2 9.62  2.57 12.41  3.20 0.001
EEM CSA, mm2 20.02  5.29 21.38  5.41 0.708
Plaque burden, % 53.7  7.9 41.2  10.2 0.001
alues represent mean  1 SD.
CSA  cross-sectional area; EEM  external elastic membrane; other abbrevia-
ions as in Table 1.
able 5. Patients With Angiographic Restenosis
Age, Gender Lesion Location Stenting Strat
62, M Bifurcation Kissing stenting
65, F Bifurcation Kissing stenting
54, M Bifurcation Stenting across the
65, M Bifurcation Crush technique
54, M Bifurcation Crush technique
73, M Bifurcation Kissing stentingCX  left circumflex artery.he SES group than the BMS group. In the SES group, all
estenoses occurred in patients with bifurcation LMCA
esions, with two in the main vessels and four at the ostial
CX (Table 5).
Clinical follow-up information was collected on all pa-
ients in the two groups. The mean clinical follow-up
uration was 11.7 3.4 months in the SES group and 30.3
3.7 months in the BMS group. At one-year follow-up,
here were no deaths or acute MIs in either group. Target
esion revascularization at one year was performed in two
ES patients (2.0%) and 21 BMS patients (17.4%) (p 
.001). Information about patients with target lesion revas-
ularization is shown in Table 5. In the SES group, four
atients with restenoses at the LCX ostium did not undergo
arget lesion revascularization as there were no ischemic
ymptoms. At 12 months, the MACE-free survival rate was
8.0 1.4% in the SES group and 81.4 3.7% in the BMS
roup (p  0.0003) (Fig. 1).
ISCUSSION
he present study found that SES implantation for patients
ith unprotected LMCA lesions and normal left ventricular
unction was safe, was associated with a low procedure-
elated complication rate, and was followed by no episodes
f death or stent thrombosis. This is similar to BMS
mplantation. In addition, despite more complex patient and
Location of
Restenosis
Target Lesion
Revascularization
Proximal edge of stents Repeat kissing stenting
Stented segment Bypass surgery
LCX ostium None
LCX ostium None
LCX ostium None
LCX ostium None
igure 1. Kaplan-Meier curves for one-year MACE-free survival in
atients treated with sirolimus-eluting stents (SES group) and bare metal
tents (BMS group). A statistically significant difference was observed
etween the two groups (p  0.0003). MACE  major adverse cardiac
vents including death, myocardial infarction, and target lesion revascular-
zation.egy
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February 1, 2005:351–6 Left Main Stenting With Sirolimus-Eluting Stentesion characteristics, the target lesion revascularization rate
f 2.0% and the restenosis rate of 7.0% in the SES group
ere less than after BMS implantation, indicating that SES
s more effective in preventing in-stent restenosis compared
o BMS.
There are few reports regarding implantation of drug-
luting stents for LMCA stenosis. Two papers from the
ESEARCH registry reported favorable results of SES
mplantation in LMCA stenoses (11,12). However, those
tudies involved small populations, included emergent in-
erventions or protected LMCA stenoses, and had limited
ngiographic follow-up. In contrast, the present study
ncluded a large number of elective patients with unpro-
ected LMCA stenoses. In addition, this study compared
utcomes of SES with contemporary BMS implantation.
The design of the current study was such that BMS
atients were treated between March 2001 and March 2003
n the pre-SES era, whereas SES patients were treated in
he subsequent period between March 2003 and March
004. Although the study was conducted over a relatively
hort period (three years), the two groups showed significant
ifferences in terms of clinical characteristics and underwent
ifferent stenting strategies. Patients undergoing SES im-
lantation were treated with a less restrictive interventional
pproach, similar to the RESEARCH registry (19).
irolimus-eluting stent patients showed more complex
aseline clinical characteristics than BMS patients, which
ed to an expectation of greater procedural and long-term
omplications (20). The SES patients included more mul-
ivessel disease, more bifurcation lesions, and longer lesion
engths. This difference in preoperative characteristics be-
ween the two groups was due to our expectation that the
emarkable benefits of SES observed in the RAVEL and the
IRIUS trials might extend to more complex lesions
9,10,19). The stenting strategy was also different for the
MS procedure compared to the SES procedure. To avoid
rterial trauma outside the stented segment, direct stenting
ithout predilation followed by postdilation with an addi-
ional balloon were performed more frequently in SES
atients compared to BMS patients (21).
There is a favorable initial outcome after LMCA inter-
ention using BMS in low-risk patients (1–3,5,7). However,
n-stent restenosis after BMS implantation is the most
mportant reason for bypass surgery as the first choice for
reating LMCA stenosis. In-stent restenosis in these pa-
ients not only influences long-term survival, but may also
ake repeat intervention so difficult that surgery is required
5). Despite endeavors to decrease in-stent restenosis after
MCA intervention using BMS, such as using aggressive
ebulking atherectomy, the restenosis rate remains at 20%
o 30% (1,5,8). In the present study, BMS implantation
ith more use of debulking atherectomy achieved larger
umen gain than SES implantation (2). However, SES was
ssociated with less angiographic restenosis and less target
esion revascularization compared to BMS. These results
ndicate that SES implantation may be very effective inuppressing intimal growth even in complex LMCA lesions
nd may lead to an excellent long-term clinical outcome.
A recent study reported that LMCA stenting using a 3.0
m SES resulted in a relatively high target lesion revascu-
arization rate (18.7%), suggesting that a 3.0 mm stent
ight not achieve adequate or homogenous drug delivery in
arge vessels such as the LMCA (22). In the present study,
6 SES patients received stents of 3.0 mm, and 18% of
otal patients underwent IVUS-guided extreme overdilation
ith a balloon 1 mm larger than the nominal stent size
23). However, restenosis in the main LMCA vessel oc-
urred in only 2.0% of SES patients. Thus, LMCA SES
mplantation appears to be a highly efficient treatment, even
hen stents larger than 3.5 mm are not available.
Bifurcation LMCA lesions are considered inappropriate
or percutaneous intervention owing to the technical diffi-
ulties of stenting and the possible narrowing of the large
ide branches (left anterior descending artery or LCX) after
tenting. The first clinical randomized study using SES for
ifurcation coronary lesions showed a very low restenosis
ate in the main vessel compared with historical controls
24). However, the study did not reveal a benefit of side
ranch SES over balloon angioplasty in terms of side branch
atency. In the present study, the higher overall restenosis
ate in bifurcation lesions (6/61 patients, 9.8%) compared to
roximal lesions (0 of 25 patients, 0%) after SES implan-
ation indicates that treatment of bifurcation lesions remains
hallenging even in the era of drug-eluting stents
14,24,25). However, the present results showing very low
estenosis rates in the main vessel and a very low frequency
f target lesion revascularization indicate that the LMCA
ifurcation may become an inviting target for percutaneous
ntervention with SES.
It is pertinent to note that the findings are based on a
elatively short-term, single-center observational study. Fur-
hermore, the number of study patients was too small to
eneralize our results to all patients with LMCA lesions.
owever, the present study provides important new infor-
ation regarding the safety and effectiveness of SES im-
lantation for unprotected LMCA stenosis. These data
ncourage the undertaking of a large, long-term, multi-
enter randomized study to compare SES implantation and
ypass surgery for unprotected LMCA stenosis.
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epartment of Medicine, University of Ulsan College of Medi-
ine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu,
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